Application of psoralen as an Nrf2 agonist in drug preparation
By directly targeting and binding to the Nrf2 protein with psoralen, its stability and phosphorylation are improved, the Nrf2 signaling pathway is activated, and various drug formulations are prepared. This solves the toxicity and compatibility problems of existing Nrf2 agonists and achieves safe, low-toxicity antioxidant and anti-inflammatory effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- CENT HOSPITAL OF MINHANG DISTRICT SHANGHAI
- Filing Date
- 2026-05-30
- Publication Date
- 2026-06-30
AI Technical Summary
Existing Nrf2 agonists suffer from problems such as high toxicity, poor biocompatibility, single target, and unstable metabolism in vivo. There is a lack of safe, low-toxicity, and naturally derived Nrf2 agonists.
Using psoralen as an Nrf2 agonist, drugs can be prepared by directly targeting and binding to the Nrf2 protein, improving its stability and phosphorylation, activating the Nrf2 signaling pathway, and developing oral, injectable, topical, and nebulized formulations.
It achieves safe and low-toxicity cell protection and tissue repair, and has multiple effects such as anti-oxidation, anti-inflammation and anti-ferroptosis, and is suitable for a variety of drug formulations.
Smart Images

Figure CN122297463A_ABST